>What if cures already exist?
>What about the billions (public/private/govt) provided to fund cure dev?
>Sheep.
>These people are sick!
>Q
Taurolidine, a Safe and Effective Anti-microbial and Anti-Cancer Drug that Never Made it to Market. by researchanon
Dr. Paul Calabresi was a pioneer in developing drugs to treat Hodgkin's lymphoma, breast cancer and prostate cancer. He served on presidential advisory panels and taught medicine at Yale and Brown Universities and was an early advocate of combination chemotherapy and gained a reputation for his innovative approach to identifying potential anti-cancer drugs. Dr. Calabresi would start with a drug that interested him and screen various kinds of tumors to find a suitable match. Using this approach, he was often on the cutting edge in terms of finding the newest agent. In September 2001, Dr. Calabresi published the amazing discovery of potent anticancer properties of an antibiotic known as taurolidine, which was effective against all tested tumors cell types (ovary, prostate, brain, lung, and melanoma) without killing normal cells. Surprisingly, the anti-cancer effects of taurolidine were found to be approximately 100-fold lower that that required for its antibiotic effects. This difference in effective doses, combined with observed low clinical toxicities of taurolidine, suggested that this safe antibiotic had an exploitable therapeutic index as an antineoplastic.
Dr. Calabresi promptly filed a use patent for Taurolidine (TRD), which was licensed to Carter-Wallace, Inc., which was then acquired by Medpoint, a subsidiary of the Carlyle Group, where, in my opinion, it was essentially “shelved.” Ironically, Dr. Paul Calabresi died of tongue cancer in 2003 at the age of 73.
Since then, substantial evidence has been reported for antineoplastic activities of TRD using animal models of bladder carcinoma, colon cancer, epithelioid cell sarcoma, esophageal cancer, fibrosarcoma, gallbladder cancer, glioblastoma, leiomyosarcoma, lung cancer, mesothelioma, melanoma, osteosarcoma, ovarian cancer, pancreas carcinoma, prostate cancer and rhabdomyosarcoma. While promising results were even obtained with TRD in some test patients, a comprehensive phase III clinical evaluation of TRD as a monotherapy for any cancer has never been conducted. Total daily doses of up to 40g and total cumulative doses exceeding 300g were found safe and well tolerated!
Because most of the business decisions about which drugs go thru the market approval process are made behind closed doors, we may never know the exact reason(s) why Taurolidine was held back. But, the writing is on the wall, potential “cures” are too often killed before they ever have a chance to be proven. The risks of approving such a nontoxic cancer drug to the high profit market share and/or to the scientific dogma are far, far too great to allow it to happen.
Taurolidine: Cytotoxic and Mechanistic Evaluation of a Novel Antineoplastic Agent. CANCER RESEARCH 61, 6816–6821, September 15, 2001. http:// cancerres.aacrjournals.org/content/61/18/6816.full-text.pdf
Redox-directed cancer therapeutics: Taurolidine and Piperlongumine as broadly effective antineoplastic agents (Review) International Journal of Oncology 45(4):1329-1336 July 28, 2014 https:// www.spandidos-publications.com/ijo/45/4/1329/download
Taurolidine cooperates with antineoplastic drugs in neuroblastoma cells. Genes & Cancer. 2014;5(11-12):460-469.